atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
A major workforce optimisation programme has started at the Countess of Chester Hospital NHS Foundation Trust in partnership with workforce planning specialists, SARD.
Read more here.
Nursing education is really no longer limited to textbooks and clinical rotations. The accelerated embrace of digital technologies is transforming the way future nurses learn, with education becoming more accessible, flexible and interactive. Technology, ranging from AI-powered tutoring systems to…
Attendees
Sponsors and
Exhibitors
AI Training
for Doctors Workshops
Contact us